Ozempic maker Novo Nordisk prepared to enter India despite patent expiry, generic competition
[ad_1] Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year. “Even as we face patent expiration for Semaglutide, we’ll probably still launch the product in markets and [drive] volume growth, and to do that we need to have…